Clemastine Treatment in Individuals With Williams Syndrome

Launched by SHEBA MEDICAL CENTER · Oct 11, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called Clemastine on individuals with Williams syndrome, a genetic condition that can affect social skills, movement, and thinking abilities. The researchers want to see if Clemastine can help improve these challenges in people aged 6 to 30 who have been diagnosed with Williams syndrome through genetic testing.

To participate in the trial, individuals must be between the ages of 6 and 30 and have a confirmed diagnosis of Williams syndrome. They should not have recently changed their medications or have any other significant health issues. During the trial, participants will take Clemastine and be monitored for changes in their social, motor, and cognitive skills. It’s important to know that this study is currently looking for participants, and those interested should discuss it with their healthcare provider to see if they meet the criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals with Williams syndrome, which has been confirmed by genetic testing.
• • Ages 6-30.
• • Normal values in safety variables (e.g. Normal ECG 120-129/80-84).
• • No change in psychotropic medications and dosage during the last 4 weeks.
• • During the study, no pharmacological change that may impact the study (e.g. ADHD
• • medications).
• Exclusion Criteria:
• • Individuals with another genetic disorder besides Williams syndrome.
• • Individuals with Williams syndrome, younger than 6 or older than 30 years old.
• • Significant change in normal values in safety variables (e.g. high or low ECG).
• • Change in medications and dosage during the last 4 weeks prior the beginning and
• • during the study.
• • Pregnancy.
• • Using addictive substances such as alcohol.